Literature DB >> 31265214

Clinical relevance of metal artefact reduction in computed tomography (iMAR) in the pelvic and head and neck region: Multi-institutional contouring study of gross tumour volumes and organs at risk on clinical cases.

Marius Hagen1, Matthias Kretschmer2, Florian Würschmidt2, Tobias Gauer3, Christian Giro2, Elias Karsten4, Jörn Lorenzen2.   

Abstract

INTRODUCTION: Artefacts caused by dental implants and hip replacements may impede target volume definition and dose calculation accuracy. The iterative metal artefact reduction (iMAR) algorithm can provide a solution for this problem. The present study compares delineation of gross tumour volumes (GTVs) and organs at risk (OARs) in the pelvic and the head and neck (H & N) regions using computed tomography (CT) with and without iMAR, and thus the practical applicability of iMAR for routine clinical use.
METHODS: The native planning CT and CT-iMAR data of two typical clinical cases with image-distorting artefacts were used for multi-institutional contouring and analysis using the Dice similarity coefficient (DSC). GTV/OAR contours were compared with an intraobserver approach and compared to predefined reference structures.
RESULTS: Mean volume for GTVprostate in the intraobserver approach decreased from 87 ± 44 cm3 (native CT) to 75 ± 22 cm3 (CT-iMAR) (P = 0.168). Compared to the reference, DSC values for GTVP rostate increased from 0.68 ± 0.15 to 0.78 ± 0.07 (CT vs. iMAR) (P < 0.05). In the H & N region, the reference for GTVT ongue (34 cm3 ) was underestimated on both data sets. No significant improvement in DSC values (0.83 ± 0.06 (native CT) versus 0.86 ± 0.06 (CT-iMAR)) was observed.
CONCLUSION: The use of iMAR improves the anatomical delineation at the transition of prostate and bladder in cases of bilateral hip replacement. In the H & N region, anatomical residual structures and experience were apparently sufficient for precise contouring.
© 2019 The Authors. Journal of Medical Imaging and Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  zzm321990iMARzzm321990; Dice similarity coefficient; contouring study; iterative metal artefact reduction; target volume definition

Mesh:

Substances:

Year:  2019        PMID: 31265214     DOI: 10.1111/1754-9485.12924

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses.

Authors:  Andrea M Fischer; Peter J Hoskin
Journal:  Radiat Oncol       Date:  2022-01-17       Impact factor: 3.481

2.  Impact of Different Metal Artifact Reduction Techniques on Attenuation Correction of Normal Organs in 18F-FDG-PET/CT.

Authors:  Janna Morawitz; Ole Martin; Johannes Boos; Lino M Sawicki; Katrin Wingendorf; Martin Sedlmair; Eduards Mamlins; Christina Antke; Gerald Antoch; Benedikt M Schaarschmidt
Journal:  Diagnostics (Basel)       Date:  2022-02-01

3.  Impact of metal artifact reduction algorithm on gross tumor volume delineation in tonsillar cancer: reducing the interobserver variation.

Authors:  Yoshiyuki Fukugawa; Ryo Toya; Tomohiko Matsuyama; Takahiro Watakabe; Yoshinobu Shimohigashi; Yudai Kai; Tadashi Matsumoto; Natsuo Oya
Journal:  BMC Med Imaging       Date:  2022-09-06       Impact factor: 2.795

4.  Geometric and dosimetric impact of 3D generative adversarial network-based metal artifact reduction algorithm on VMAT and IMPT for the head and neck region.

Authors:  Mitsuhiro Nakamura; Megumi Nakao; Keiho Imanishi; Hideaki Hirashima; Yusuke Tsuruta
Journal:  Radiat Oncol       Date:  2021-06-06       Impact factor: 3.481

5.  Dosimetric impact of using a commercial metal artifact reduction tool in carbon ion therapy in patients with hip prostheses.

Authors:  Jingfang Zhao; Weiwei Wang; Kambiz Shahnaz; Xianwei Wu; Jingfang Mao; Ping Li; Qing Zhang
Journal:  J Appl Clin Med Phys       Date:  2021-06-23       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.